A Lyme disease mRNA vaccine targeting <i>Borrelia burgdorferi</i> OspA induces strong immune responses and prevents transmission in mice.

ABSTRACT: Lyme borreliosis (LB), caused by Borrelia burgdorferi sensu lato, is one of the most common tick-borne diseases in the northern hemisphere. Given its increasing global incidence, LB remains a major public health concern and the development of an effective vaccine is recognized as a key component of the overall disease prevention strategy. Here, we present results obtained with newly developed lipid nanoparticle-encapsulated mRNA vaccine candidates encoding the outer surface protein A (OspA) of B. burgdorferi sensu stricto (Bbss) serotype 1 (mRNA-OspA) with or without a secretion signal (SS) or a transmembrane domain. We evaluated the immunogenicity and protective efficacy of the mRNA-OspA vaccine candidates in a tick-fed mouse challenge model compared with an adjuvanted OspA

SUBMITTER: Tahir D 

PROVIDER: S-EPMC11986965 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature